MRNA · News · 20260807N

Revenue Performance and Mix

Moderna, Inc. · 2026-08-07 · Importance 74 · Surprise 32

Moderna reported second-quarter 2026 revenue of $145 million, exceeding analysts’ estimates. The company posted a GAAP loss of $1.97 per share for the quarter. Management reiterated a 2026 revenue-growth target of up to 10%, indicating an expected recovery from pandemic-era COVID vaccine revenue declines through newer products and pipeline programs.

Key facts

• Moderna reported revenues of $145 million, exceeding estimates, and a GAAP loss of $1.97 per share, matching expectations. source